pralsetinib 100 MG Oral Capsule

RxCUI: 2394941
RxNorm name: pralsetinib 100 MG Oral Capsule
Display name: pralsetinib 100 MG Oral Capsule
Full name: pralsetinib 100 MG Oral Capsule
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:59

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Gavreto	PRALSETINIB	Rigel Pharmaceuticals, Inc.	16edd46e-28b8-f06d-e063-6394a90ae31b	2025-12-30	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2394941
Gavreto	PRALSETINIB	Genentech, Inc.	59984249-e3ff-4f97-8d7a-c1a905d604a8	2025-12-05	Warnings, Adverse reactions	Exact identifier rxcui: 2394941

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
59984249-e3ff-4f97-8d7a-c1a905d604a8	pralsetinib 100 MG Oral Capsule [PSN] · pralsetinib 100 MG Oral Capsule [SCD]	2	18	These highlights do not include all the information needed to use GAVRETO safely and effectively. See full prescribing information for GAVRETO. GAVRETO ® (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020	20251205
16edd46e-28b8-f06d-e063-6394a90ae31b	pralsetinib 100 MG Oral Capsule [PSN] · pralsetinib 100 MG Oral Capsule [SCD]	2	8	These highlights do not include all the information needed to use GAVRETO safely and effectively. See full prescribing information for GAVRETO. GAVRETO ® (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020	20251230